IBRX Stock Forecast: $12.60 Target on Cancer Drug Progress
IBRX stock forecast targets $12.60 amid promising cancer trials. Check IBRX stock price, earnings, technical analysis, and if IBRX stock is a buy. March 2026 data. Introduction ImmunityBio (IBRX) develops cancer immunotherapies and vaccines. It targets hard-to-treat tumors with T-cell therapies. IBRX stock grabs attention after FDA approvals and trial data releases. Biotech investors watch … Read more